Target regimen profiles for TB treatment: candidates: rifampicin-susceptible, rifampicinresistant and pan-TB treatment regimens

Overview

There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regimen characteristics corresponding to the needs of end-users. The proposed TRPs have been developed in a multi-stakeholder process led by the Global TB Programme and the WHO Task Force on New TB Drug Policy Development, with the collaboration of the Johns Hopkins University and the participation of a large array of stakeholders. This work was supported by a grant from the Bill & Melinda Gates Foundation.

• Report of the Consensus meeting for finalization of Target Regimen Profiles for TB treatment: 7-8 July 2016, Geneva, Switzerland